Effect of oral ferric citrate on serum phosphorus in hemodialysis patients

multicenter, randomized, double-blind, placebo-controlled study

Chien Te Lee, I. Wen Wu, Shou Shan Chiang, Yu Sen Peng, Kuo Hsiung Shu, Ming Ju Wu, Mai Szu Wu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.

Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.

Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p 

Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.

Original languageEnglish
Pages (from-to)105-113
Number of pages9
JournalJournal of Nephrology
Volume28
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Phosphorus
Renal Dialysis
Hyperphosphatemia
Placebos
Serum
Transferrin
Ferritins
Phosphates
Taiwan
Chronic Kidney Failure
Dialysis
Randomized Controlled Trials
Maintenance
ferric citrate
Calcium
Safety
Therapeutics

Keywords

  • Ferric citrate
  • Hemodialysis
  • Iron metabolism
  • Phosphate

ASJC Scopus subject areas

  • Nephrology

Cite this

Effect of oral ferric citrate on serum phosphorus in hemodialysis patients : multicenter, randomized, double-blind, placebo-controlled study. / Lee, Chien Te; Wu, I. Wen; Chiang, Shou Shan; Peng, Yu Sen; Shu, Kuo Hsiung; Wu, Ming Ju; Wu, Mai Szu.

In: Journal of Nephrology, Vol. 28, No. 1, 2014, p. 105-113.

Research output: Contribution to journalArticle

Lee, Chien Te ; Wu, I. Wen ; Chiang, Shou Shan ; Peng, Yu Sen ; Shu, Kuo Hsiung ; Wu, Ming Ju ; Wu, Mai Szu. / Effect of oral ferric citrate on serum phosphorus in hemodialysis patients : multicenter, randomized, double-blind, placebo-controlled study. In: Journal of Nephrology. 2014 ; Vol. 28, No. 1. pp. 105-113.
@article{eec4a46dfb2a47179e7a6237a3dbf68d,
title = "Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study",
abstract = "Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.",
keywords = "Ferric citrate, Hemodialysis, Iron metabolism, Phosphate",
author = "Lee, {Chien Te} and Wu, {I. Wen} and Chiang, {Shou Shan} and Peng, {Yu Sen} and Shu, {Kuo Hsiung} and Wu, {Ming Ju} and Wu, {Mai Szu}",
year = "2014",
doi = "10.1007/s40620-014-0108-6",
language = "English",
volume = "28",
pages = "105--113",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Effect of oral ferric citrate on serum phosphorus in hemodialysis patients

T2 - multicenter, randomized, double-blind, placebo-controlled study

AU - Lee, Chien Te

AU - Wu, I. Wen

AU - Chiang, Shou Shan

AU - Peng, Yu Sen

AU - Shu, Kuo Hsiung

AU - Wu, Ming Ju

AU - Wu, Mai Szu

PY - 2014

Y1 - 2014

N2 - Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.

AB - Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.

KW - Ferric citrate

KW - Hemodialysis

KW - Iron metabolism

KW - Phosphate

UR - http://www.scopus.com/inward/record.url?scp=84922574601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922574601&partnerID=8YFLogxK

U2 - 10.1007/s40620-014-0108-6

DO - 10.1007/s40620-014-0108-6

M3 - Article

VL - 28

SP - 105

EP - 113

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 1

ER -